Trials / Approved For Marketing

Approved For MarketingNCT02307812

Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France

Status: Approved For Marketing
Phase: —
Study type: Expanded Access
Enrollment: —

Sponsor: Eli Lilly and Company · Industry
Sex: All
Age: —
Healthy volunteers: —

Summary

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the ATU.

Conditions

Gastric Cancer
Gastroesophageal Junction Adenocarcinoma

Interventions

Type	Name	Description
DRUG	Ramucirumab	Administered intravenously (IV)
DRUG	Paclitaxel	Administered IV

Timeline

First posted: 2014-12-04
Last updated: 2025-01-09

Source: ClinicalTrials.gov record NCT02307812. Inclusion in this directory is not an endorsement.